Skip to content
Catalyst

Silybum marianumFinding

Silybum marianum decreases glycated haemoglobin (HbA1c)

lowersVery limited evidenceFinding

01 · The sentence it was drawn from

“The results showed a significant decrease in HbA(1)c, FBS, total cholesterol, LDL, triglyceride SGOT and SGPT levels in silymarin treated patients compared with placebo as well as with values at the beginning of the study in each group.”
Quoted verbatim from The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
This finding among the 73 findings on its endpoint

Silybum marianum

Glycated haemoglobin (HbA1c)

lowers

Who
adults with type II diabetes, conventional therapy continued in both arms
Dose studied
silymarin 200 mg tablet three times daily for 4 months

Very limited evidencePMID 17072885 · 2006

02 · The study

Study
RCT
Duration
not reported

Evidence, by strength

  • strong
  • moderate
  • limited
  • very limitedthis finding
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M7FQ35BJRFM7D226310GJ5TX